CAS 385367-47-5|Tarafenacin

Introduction：Basic information about CAS 385367-47-5|Tarafenacin, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Tarafenacin BiologicalActivity
3. Chemical & Physical Properties
4. Synonyms

Common Name	Tarafenacin
CAS Number	385367-47-5	Molecular Weight	408.389
Density	1.4±0.1 g/cm3	Boiling Point	483.4±45.0 °C at 760 mmHg
Molecular Formula	C₂₁H₂₀F₄N₂O₂	Melting Point	/
MSDS	/	Flash Point	246.2±28.7 °C

Names

Name	[(3R)-1-azabicyclo[2.2.2]octan-3-yl] N-(3-fluorophenyl)-N-[(3,4,5-trifluorophenyl)methyl]carbamate
Synonym	More Synonyms

Tarafenacin BiologicalActivity

Description	Tarafenacin(SVT-40776) is a highly selective M3 muscarinic receptor antagonist (Ki= 0.19 nM), ~200 fold selectivity over M2 receptor.IC50 value: 0.19 nM (Ki) [1]Target: M3 muscarinic receptorin vitro: SVT-40776 is highly selective for M(3) over M(2) receptors (Ki = 0.19 nmol.L(-1) for M(3) receptor affinity). SVT-40776 was the most potent in inhibiting carbachol-induced bladder contractions of the anti-cholinergic agents tested, without affecting atrial contractions over the same range of concentrations. SVT-40776 exhibited the highest urinary versus cardiac selectivity (199-fold) [1]. SVT-40776 has a much higher binding affinity (K(d) = 0.4 nM) to M5 mAChR than that of solifenacin (K(d) = 31 nM) with the same reeptor. The calculated binding free energy change (-2.3 ± 0.3 kcal/mol) from solifenacin to SVT-40776 is in good agreement with the experimentally derived binding free energy change (-2.58 kcal/mol), suggesting that our modeled M5 mAChR structure and its complexes with the antagonists are reliable [2].in vivo: In the guinea pig in vivo model, SVT-40776 inhibited 25% of spontaneous bladder contractions at a very low dose (6.97 microg.kg(-1) i.v), without affecting arterial blood pressure [1].
Related Catalog	Signaling Pathways >>GPCR/G Protein >>mAChRSignaling Pathways >>Neuronal Signaling >>mAChRResearch Areas >>Neurological Disease
References	[1]. Salcedo C, et al. In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. Br J Pharmacol. 2009 Mar;156(5):807-17. [2]. Huang X, et al. Microscopic binding of M5 muscarinic acetylcholine receptor with antagonists by homology modeling, molecular docking, and molecular dynamics simulation. J Phys Chem B. 2012 Jan 12;116(1):532-41.

Description

Tarafenacin(SVT-40776) is a highly selective M3 muscarinic receptor antagonist (Ki= 0.19 nM), ~200 fold selectivity over M2 receptor.IC50 value: 0.19 nM (Ki) [1]Target: M3 muscarinic receptorin vitro: SVT-40776 is highly selective for M(3) over M(2) receptors (Ki = 0.19 nmol.L(-1) for M(3) receptor affinity). SVT-40776 was the most potent in inhibiting carbachol-induced bladder contractions of the anti-cholinergic agents tested, without affecting atrial contractions over the same range of concentrations. SVT-40776 exhibited the highest urinary versus cardiac selectivity (199-fold) [1]. SVT-40776 has a much higher binding affinity (K(d) = 0.4 nM) to M5 mAChR than that of solifenacin (K(d) = 31 nM) with the same reeptor. The calculated binding free energy change (-2.3 ± 0.3 kcal/mol) from solifenacin to SVT-40776 is in good agreement with the experimentally derived binding free energy change (-2.58 kcal/mol), suggesting that our modeled M5 mAChR structure and its complexes with the antagonists are reliable [2].in vivo: In the guinea pig in vivo model, SVT-40776 inhibited 25% of spontaneous bladder contractions at a very low dose (6.97 microg.kg(-1) i.v), without affecting arterial blood pressure [1].

Related Catalog

Signaling Pathways >>GPCR/G Protein >>mAChRSignaling Pathways >>Neuronal Signaling >>mAChRResearch Areas >>Neurological Disease

References

[1]. Salcedo C, et al. In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. Br J Pharmacol. 2009 Mar;156(5):807-17.

[2]. Huang X, et al. Microscopic binding of M5 muscarinic acetylcholine receptor with antagonists by homology modeling, molecular docking, and molecular dynamics simulation. J Phys Chem B. 2012 Jan 12;116(1):532-41.

Chemical & Physical Properties

Density	1.4±0.1 g/cm3
Boiling Point	483.4±45.0 °C at 760 mmHg
Molecular Formula	C₂₁H₂₀F₄N₂O₂
Molecular Weight	408.389
Flash Point	246.2±28.7 °C
Exact Mass	408.146088
PSA	32.78000
LogP	4.59
Vapour Pressure	0.0±1.2 mmHg at 25°C
Index of Refraction	1.587
InChIKey	UXZDMXYRRQJIBJ-IBGZPJMESA-N
SMILES	O=C(OC1CN2CCC1CC2)N(Cc1cc(F)c(F)c(F)c1)c1cccc(F)c1
Storage condition	2-8℃

Synonyms

Tarafenacin

UNII-LDV98UN52Y

Carbamic acid, N-(3-fluorophenyl)-N-[(3,4,5-trifluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester

(3R)-1-Azabicyclo[2.2.2]oct-3-yl (3-fluorophenyl)(3,4,5-trifluorobenzyl)carbamate

(3R)-1-Az2,4(1Habicyclo(2.2.2)octan-3-yl (3-fluorophenyl)((3,4,5-trifluorophenyl)methyl)carbamate

Tarafenacin [INN]

Recommended......